NEW YORK (GenomeWeb News) – Contract research organization Reaction Biology (RBC) said today that it has signed an agreement with Cisbio Bioassays for distribution of its epigenetic proteins.

The agreement gives Cisbio global rights to co-market and sell RBC's epigenetic proteins. Cisbio can include these proteins in its portfolio of assays, including recently added assays for assessing epigenetic targets like methyltransferases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.